New targeted drug ZV0203 enters first human tests for Hard-to-Treat HER2 cancers
Disease control
ENROLLING_BY_INVITATION
This early-stage trial is testing a new drug, ZV0203, in 36 adults with HER2-positive advanced solid tumors that have not responded to standard treatments. ZV0203 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to HER2-positive tumor cells. The m…
Phase: PHASE1 • Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC